Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1341-1360 of 2,120 trials

Metastatic Colorectal Cancer: Trifluridine/Tipiracil with Panitumumab vs. Bevacizumab

We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Angiosarcoma and Undifferentiated Pleomorphic Sarcoma: Propranolol and Pembrolizumab Study

We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.

Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer Prevention: Denosumab for Women with BRCA1 Mutation

We are studying whether Denosumab can help prevent breast cancer in women carrying a BRCA1 mutation. This trial compares its effects to a placebo to see if it reduces cancer risk.

Breast Cancer Prevention in BRCA1 Mutation Carriers>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteHematologyOncology

Karonudib for Blood Cancers: Phase 1 Study

We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.

Blood Cancers>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Kidney Transplant: Eight Treg Immunotherapy

We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.

Chronic Kidney FailureSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Rare Cancers: Targeted Drug Study

We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.

Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Knee Surgery Pain Relief: Nefopam Study

We are investigating whether an oral medication called nefopam can reduce morphine use after total knee replacement surgery. This study aims to improve pain management for adults recovering from this procedure.

Postoperative Pain After Knee Surgery>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineOrthopedics and Traumatology

Esophageal Cancer: Trastuzumab and Pertuzumab Study

We are studying if adding trastuzumab and pertuzumab to standard treatment helps improve survival for patients with HER2 positive esophageal adenocarcinoma. This trial involves patients whose cancer can be surgically removed.

HER2 Positive Esophageal Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Cardiogenic Shock: Levosimendan vs. Placebo

We are studying whether early use of levosimendan can improve health outcomes in patients with cardiogenic shock compared to a placebo. The goal is to see if it reduces the need for life support and improves survival rates.

Cardiogenic Shock>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Leiomyosarcoma: Trabectedin vs. Gemcitabine

We are comparing two treatments, Trabectedin and Gemcitabine, for patients with advanced leiomyosarcoma who have already received chemotherapy. The goal is to see which treatment works better in slowing down cancer growth and improving survival.

Leiomyosarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cerebrolysin for CADASIL Patients

We are studying whether Cerebrolysin is safe and effective for individuals with genetically confirmed CADASIL. This trial compares it to a placebo to understand its overall benefits.

CADASIL>2 yearsEfficacy phase (II)>20 visitsStandard MedicinesNeurology

Colorectal Cancer: Amivantamab with Chemotherapy

We are comparing a new treatment combining Amivantamab and chemotherapy to Cetuximab with chemotherapy for patients with certain types of colorectal cancer. This study aims to find out which option may help patients live longer without their cancer worsening.

Left-sided Colorectal CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Chronic Rhinosinusitis with Nasal Polyps: Tezepelumab Study

We are investigating how tezepelumab affects symptoms in adults with chronic rhinosinusitis and nasal polyps. The study looks at changes in nasal congestion, sense of smell, and overall quality of life.

Chronic Rhinosinusitis with Nasal Polyps3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Chronic Kidney Disease: Sevuparin Treatment Study

We are investigating how sevuparin may improve kidney function and anemia in people with chronic kidney disease. The study will assess safety and how the drug works in the body.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology

Cluster Headache Study: Understanding Brain Activity

We are exploring how brain activity and receptor availability differ in people with cluster headaches during active and inactive periods. This research may help us learn more about the condition and its effects on the brain.

Nervous System Diseases>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Glucose Distribution in Severely Burned Adults

We are studying how glucose is distributed in the bodies of severely burned adults during their first few days of treatment. This research may help us understand its relationship with other health factors and improve patient care.

Severe Burns>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyInternal MedicineOrthopedics and Traumatology

Pancreatic Cancer: TCR-Modified T-Cell Therapy

We are studying a new therapy using modified T-cells for adults with advanced pancreatic cancer that has specific genetic mutations. The trial aims to assess safety and how well this treatment may work.

Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Sickle Cell Disease: Gene Therapy with Lovocel

We are studying the long-term safety and effectiveness of a new gene therapy for people with sickle cell disease. This treatment uses modified stem cells to potentially improve health outcomes.

Sickle Cell DiseaseConfirmation phase (III)No PlaceboInvestigational MedicinesHematology

HIV Treatment: IMC-M113V Study

We are evaluating a new treatment, IMC-M113V, for people with chronic HIV infection who are already on medication. The study will help us understand its safety and how it affects the immune system.

Chronic HIV Infection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine